Luca Vincenzo Cappelli | Ricerc@Sapienza

Pubblicazioni

Titolo	Pubblicato in	Anno
Spontaneous regression in chronic lymphocytic leukaemia. Clinical features of 50 cases from the ERIC registry and review of the literature.	BRITISH JOURNAL OF HAEMATOLOGY	2023
Biomarkers in acute myeloid leukemia: From state of the art in risk classification to future challenges of RNA editing as disease predictor and therapy target	ASPECTS OF MOLECULAR MEDICINE	2023
BH3 mimetics in relapsed and refractory adult acute lymphoblastic leukemia: a Campus ALL real-life study	HAEMATOLOGICA	2023
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia	HAEMATOLOGICA	2022
Indeterminate and oncogenic potential: CHIP vs CHOP mutations in AML with NPM1 alteration	LEUKEMIA	2022
Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia	THE JOURNAL OF MOLECULAR DIAGNOSTICS	2022
Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression	LIFE SCIENCE ALLIANCE	2021
TH2/TH1 shift under Ibrutinib treatment in chronic lymphocytic leukemia	FRONTIERS IN ONCOLOGY	2021
PKCλ/ι inhibition activates an ULK2-mediated interferon response to repress tumorigenesis	MOLECULAR CELL	2021
In Vivo and Ex Vivo Patient-Derived Tumor Xenograft Models of Lymphoma for Drug Discovery	CURRENT PROTOCOLS	2021
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations	BRITISH JOURNAL OF HAEMATOLOGY	2020
Peripheral T cell lymphomas: from the bench to the clinic	NATURE REVIEWS CANCER	2020
A novel JAK1 mutant breast implant-associated anaplastic large cell lymphoma patient-derived xenograft fostering pre-clinical discoveries	CANCERS	2020
Minimal residual disease monitoring in early stage follicular lymphoma can predict prognosis and drive treatment with rituximab after radiotherapy	BRITISH JOURNAL OF HAEMATOLOGY	2019
Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?	FRONTIERS IN ONCOLOGY	2019
DNMT3A mutations are over-represented in young adults with NPM1 mutated AML and prompt a distinct co-mutational pattern	LEUKEMIA	2019
TP53 CLONAL AND SUBCLONAL ARCHITECTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS UNDER IBRUTINIB TREATMENT.	HemaSphere	2019
IBRUTINIB TREATMENT DOESN’T INDUCE TP53 CLONAL EVOLUTION IN CHRONIC LYMPHOCYTIC LEUKEMIA.	Haematologica 2019; 104(s2):1	2019
IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies	LEUKEMIA	2018
Biallelic BIRC3 inactivation in chronic lymphocytic leukaemia patients with 11q deletion identifies a subgroup with very aggressive disease.	BRITISH JOURNAL OF HAEMATOLOGY	2018